Elucida Oncology Inc., a biotechnology company focused on developing and commercializing a first-in-class, ultra-small nanoparticle platform technology for the diagnosis and treatment of cancer, announced today that it has appointed Robert A. Essner as its Executive Chairman.
Mr. Essner was Chairman and Chief Executive Officer for Wyeth, acquired by Pfizer in 2009. In his 32 years in the pharmaceutical industry Mr. Essner has held numerous high-level leadership roles that included Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA). He is Chairman of the not-for-profit Children’s Health Fund, and a Trustee of Mote Marine Laboratory, as well as Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in Healthcare Management.
Mr. Essner is also an Operating Executive for The Carlyle Group, and a member of the Board of Directors for Amicus Therapeutics and has just completed a 16-year term on the Board of Directors for MassMutual.
Isaac Blech, Vice Chairman of the Board of Directors of Elucida Oncology, commented, “All of us at Elucida are extremely pleased to bring an executive of Bob Essner’s stature into the company to help Elucida achieve its goal of becoming a leading precision medicine oncology company.”
“I welcome Bob to Elucida and look forward to his considerable experience being applied to the Elucida C-Dot platform as we bring to market first-in-class diagnostic and therapeutic products to positively impact the lives of cancer patients,” said Edward Rosen, Elucida’s President and Chief Executive Officer. “Bob Essner is a pivotal leader in the pharmaceutical industry. We are delighted to have Bob join us as Executive Chairman.”
“I am very excited to be part of what is being built at Elucida Oncology,” stated Mr. Essner. “Advancing innovation to change and save lives has been the core of my career for over 30 years. At Elucida, we have a remarkable first-in-class particle platform. This is a rare opportunity to make a compelling improvement to the world of precision oncology, in diagnostic and therapeutic applications. I am proud to be part of this effort and this team.”
Source: Elucida Oncology
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
